Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

FDA Announced Clearance To Instil Bio's Early-Stage ITIL-306 Study In Cancer Settings

The U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to Instil Bio’s (NASDAQ:TIL) ITIL-306 an autologous TIL cell therapy, for the treatment for patients with with non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).

ITIL-306 is company’s first genetically-engineered Costimulatory Antigen Receptor TIL (CoStAR-TIL) therapy.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.